60209-60-1

Downstream Products

• 96922-04-2 (2S,6S)-2-Benzyloxycarbonylamino-6-[(S)-4-benzyloxycarbonyl-4-((R)-2-tert-butoxycarbonylamino-propionylamino)-butyrylamino]-6-(benzyloxycarbonylmethyl-carbamoyl)-hexanoic acid ethyl ester 
• 76490-22-7 D-lactoyl-L-Ala-γ-L-Glu(α-OH)-(L)meso-A₂pm(L)-Gly 
• 76490-07-8 D-lactoyl(OAc)-L-Ala-L-Glu(OH)OBzl 
• 76490-19-2 D-lactoyl(OAc)-L-Ala-γ-L-Glu(α-OBzl)-(L)-Boc-(D)meso-A₂pm(D)-NHNHBoc-(L)-Gly 
• 79390-10-6 (S)-2-[(S)-2-((R)-2-Acetoxy-propionylamino)-propionylamino]-pentanedioic acid 1-benzyl ester; compound with dicyclohexyl-amine 
• 78665-22-2 (S)-2-((S)-2-Amino-propionylamino)-pentanedioic acid 1-benzyl ester 

Relevant academic research and scientific papers

[Asn2 ]-thymosin α1 and analogs thereof

Thymosin α1, was chemically synthesized by the fragment condensation of the protected amino terminal tetradecapeptide with the protected carboxyl terminal tetradecapeptide. Similarly prepared was the analog [Asn2 ]-thymosin α1 utilizing the appropriately modified protected amino terminal tetradecapeptide. Both products are active as agents which affect regulation, differentiation and function of thymus dependent lymphocytes (T cells).